BioNTech's $325 million Series B financing proceeds will be used not only toward advancing its pipeline of immuno-oncology candidates, but adding to its manufacturing capacity and exploring an expanded global footprint as well . . .
- GEN Edge
- News
- Genome Editing
- Gene Therapy
- Drug Discovery
- Antibodies
- Cancer
- Translational Medicine
- Infectious Diseases
- OMICs
- Monoclonal Antibodies
- RNA
- mRNA
- Gastric Cancer
- Head and Neck Cancer
- Therapeutics
- Cellular Therapeutics
- Immuno-oncology
- Immunotherapies
- Skin Cancer
- Industry News
- Peptides
